Great Lakes is pleased to announce a new partnership with OrthoApnea, the developer of an innovative mandibular advancement device called NOA, clinically proven to treat obstructive sleep apnea and snoring.
“We are impressed with OrthoApnea’s commitment to innovative, high-quality, and scientifically backed treatment solutions for patients suffering from sleep apnea and sleep-disordered breathing,” said John Ende, President, and CEO of Great Lakes. “The new NOA stands out as it was entirely developed in a digital environment, with a focus on the mandibular biomechanics of each patient throughout the appliance concept and design.”
The custom OrthoApnea NOA consists of two individual low-profile splints that hold the jaw in a controlled forward position, facilitating breathing and providing a more comfortable experience for the patient. The flexible and controlled advancement allows for lateral jaw movement while preventing joint discomfort.
The mandibular advancement is determined by the doctor and carried out progressively and in a controlled sequence through a series of lower splints.
OrthoApnea is a global, ISO-certified company that specializes in the development, production, and distribution of mandibular advancement devices for the treatment of Obstructive Sleep Apnea (OSA).
Great Lakes, an employee-owned company, offers products, laboratory appliances, services, as well as in-house and online appliance fabrication training to members of the orthodontic, prosthodontic, restorative, sleep, and general dental professions worldwide. Since its establishment as an independent orthodontic lab in 1965, Great Lakes has been a leading innovator in the dental industry.
The corporate headquarters of Great Lakes is located at 200 Cooper Avenue in Tonawanda, New York.
